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SV-IV did not induce de novo synthesis of cytokines and 
growth factors (transforming growth factor-  1 , interleukin-
10, interleukin-13, tumor necrosis factor-  , vascular endo-
thelial growth factor A) in Fc  RI+ cells.  Conclusions: SV-IV 
protein induces in human Fc  RI+ cells the release of hista-
mine, a proinflammatory, antiapoptotic and immunosup-
pressive biogenic amine. These data: (1) are consistent with 
the antiapoptotic and immunosuppressive properties of SV-
IV; (2) confirm a regulatory feature of SV-IV on mammal in-
flammatory reactivity by either inhibiting the arachidonate 
cascade pathway or stimulating proinflammatory cytokine 
release from lymphocyte/monocytes and histamine from 
Fc  RI+ cells; (3) raise the possibility of a protective role of SV-
IV on implanting hemiallogenic blastocysts against mater-
nal reactive oxygen species and immunological attacks at 
the uterine implantation site. 
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 Abstract 
 Background: Seminal vesicle protein number 4 (SV-IV) is a 
small, basic, multifunctional, intrinsically disordered secre-
tory protein synthesized in large amounts by rat seminal ves-
icle epithelium under androgen transcriptional control. SV-
IV-immunorelated proteins occur in other rat tissues and in 
humans.  Methods: The in vitro effect of SV-IV on human 
Fc  RI+ cells was investigated by standard  immunologic, 
biochemical and molecular biology procedures.  Results: SV-
IV-induced histamine release from human basophils and 
lung mast cells without any influence on leukotriene C 4 re-
lease and cell migration. The histamine release rate was 
slower compared with that induced by anti-IgE, the temper-
ature dependence of the event being similar. SV-IV-induced 
histamine release was Ca 2+ -dependent, suggesting a physi-
ological interaction of the protein with Fc  RI+ cells. SV-IV 
and anti-IgE acted synergistically on the histamine release. 
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 Introduction 
 Seminal vesicle protein No. 4 (SV-IV), according to its 
mobility in SDS-PAGE; precursor UniProtKB/Swiss-Prot 
ID, SVS4_RAT; accession No. P02783) is a purified and 
extensively characterized (M r = 9,758; pI = 8.9) multi-
functional secretory protein. It is synthesized by the rat 
seminal vesicle epithelium under androgen transcrip-
tional control  [1–5] and is encoded by a gene sequenced, 
cloned, and expressed in  Escherichia coli  [6–9] . Its poly-
peptide chain is a thermostable, intrinsically disordered 
 [10–12] and highly flexible molecule. In aqueous solution, 
it behaves as a concentration-dependent self-associating 
system (monomer  o dimer  o trimer equilibrium) in 
which the biologically active configuration is monomer-
ic and the inactive one is trimeric  [11, 12] . In the range of 
physiological concentrations (2–48   M )  [11, 13] , its bio-
logical properties are modulated by a supramolecular 
equilibrium in which the trimeric form competes with 
the monomeric one for binding to a variety of cell targets 
 [11] . SV-IV-immunorelated proteins occur in several rat 
tissues (uterus, lung, liver, brain), as well as in human 
seminal fluid and seminal vesicle secretion  [14–16] . 
 SV-IV exerts a  non-species-specific inhibitory activity 
on inflammation, cell-mediated and humoral immunity, 
and apoptosis  [13, 17–25] . In addition, it possesses a stim-
ulatory effect on purified peroxidases  [25, 26] and pro-
tects cells against oxidative-stress-induced damage, by 
acting as an indirect reactive-oxygen-species scavenger 
 [25] . Besides, SV-IV immunosuppressive properties sug-
gest a defensive role against maternal immunological at-
tack of hemiallogenic implanting blastocysts  [11, 19, 23, 
25, 27] . The anti-inflammatory effect of the protein is re-
lated to phospholipase A 2 (PLA 2 ) inhibition, while its im-
munomodulatory activity is generated by interference 
with macrophage-T cell cooperation (modulation of cy-
tokine production; inhibition of macrophage antigen 
presentation and T cell activation)  [13, 19–24, 28] .
 SV-IV induces the release of cytokines, i.e. interferon-
  (IFN-  ), granulocyte macrophage colony-stimulating 
factor (GM-CSF), tumor necrosis factor-  (TNF-  ), in-
terleukin-6 (IL-6), from human isolated resting lympho-
cytes and monocytes with proinflammatory features in 
contrast to its known anti-inflammatory properties. 
Prompted by this observation, we investigated whether 
SV-IV exerted any stimulatory or inhibitory activity on 
human cells (mast cells and basophils) positive for high-
affinity receptor I for IgE (Fc  RI+ cells). The effects of 
SV-IV on these cells have not yet been explored by our 
group.
 Mast cells and basophils are effectors of allergic reac-
tions. They express high-affinity tetrameric Fc receptors 
(  /  /  2 ) for IgE (Fc  RIs) on their surface and contain 
histamine-rich granules in their cytosol. These two at-
tributes distinguish these cells from all other human cell 
types and explain their unique role in allergic inflamma-
tion. The surface of Fc  RI+ cells is coated with IgE mol-
ecules adsorbed from the circulation and serving as re-
ceptors for specific antigens. The binding of antigens to 
IgE activates these cells, inducing their degranulation 
with release of granule content (e.g., histamine, protein-
ases, cytokines, chemokines and growth factors) into the 
surrounding medium  [29] .
 Mast cells are marrow-derived, tissue-resident ele-
ments essential for IgE-mediated inflammatory reac-
tions. They secrete a wide variety of biologically active 
substances (mediators) when stimulated by immunologi-
cal (e.g., anti-IgE and anti-Fc  RI) or nonimmunological 
secretagogue stimuli (e.g. lectins, N-formylmethionyl-
leucyl-phenylalanine, calcium ionophores and PLA 2 ). 
Fc  RI+ cells can be activated directly by pathogens (bac-
teria, viruses and parasites), by soluble products (e.g., 
proteins, oligopeptides and toxins) derived from these 
pathogens or other organic sources. Mediators released 
by mast cells have been classified as: (a) preformed me-
diators, stored in cytoplasmic granules (e.g., histamine, 
proteoglycans and various enzymes); (b) lipid mediators 
synthesized de novo [e.g., prostaglandin D 2  and leukotri-
ene C 4  (LTC 4 )], cytokines, chemokines, and growth fac-
tors  [30] . These mediators, in addition to proinflamma-
tory activity  [30] , may also have anti-inflammatory or 
immunosuppressive properties [e.g., interleukin-10 (IL-
10), transforming growth factor-  1 (TGF-  1 )]  [31, 32] 
and, frequently, promote local degradation or remodel-
ing of inflamed tissues  [33] . 
 Basophils are circulating marrow-derived cells that 
share many properties with tissue mast cells, although 
they are a distinct cell lineage and are not found in nor-
mal tissues. These cells express IL-4 and IL-13 mRNA, 
infiltrate the sites of allergic inflammation in asthmatic 
responses  [29, 34] , and are detectable in inflammatory 
infiltrates of  Helicobacter-pylori -induced gastritis  [35] . 
 The present study aimed at investigating the effect of 
SV-IV on resting or anti-IgE-stimulated Fc  RI+ cells. 
This treatment induced the release of histamine, a proin-
flammatory, antiapoptotic, and immunosuppressive bio-
genic amine  [36–41] , not associated with the secretion of 
immunosuppressive or proinflammatory cytokines or 
growth factors synthesized de novo.
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 These results: (a) are in line with the antiapoptotic and 
immunosuppressive properties of SV-IV  [13, 17, 19–24, 
28] ; (b) confirm a modulatory activity of this protein on 
mammal inflammation reactivity by either inhibiting 
the arachidonate cascade pathway  [19, 21] or stimulating 
the release of proinflammatory cytokines from lympho-
cytes/monocytes  [13] and histamine from Fc  RI+ cells; 
(c) raise the possibility of a protective role of SV-IV on 
implanting hemiallogenic blastocyst against reactive ox-
ygen species and maternal immunological attacks at the 
uterine implantation site in concert with other local im-
munosuppressive cells (mast cells and CD4+CD25+ 
FoxP3+ regulatory T cells), cytokines (TGF-  1 , IL-10), 
and antiapoptotic factors (leukemia inhibitory factor, 
heme oxygenase 1, peroxidases and histamine).
 Materials and Methods 
 Chemicals 
 The following reagents were purchased: 60% HClO 4 (Baker 
Chemical, Deventer, The Netherlands); human serum albumin, 
PIPES (Sigma, St. Louis, Mo., USA); FCS, TRIzol, and murine 
Moloney leukemia virus transcriptase (Life Technologies, Grand 
Island, N.Y., USA); RPMI-1640 (Flow Laboratories, Irvine, UK); 
dextran 70 and Percoll (Pharmacia, Uppsala, Sweden); PCR kit 
(Promega Corporation, USA). Rabbit polyclonal IgG from non-
immunized animals was obtained from Sigma. Rabbit anti-hu-
man IgE Ab was a gift from Drs. Teruko and Kimishige Ishizaka 
(La Jolla Institute for Allergy and Immunology, La Jolla, Calif., 
USA). All other reagents were of the highest purity commercially 
available.
 Buffers 
 The PIPES buffer contains 25 m M PIPES (pH 7.4), 110 m M 
NaCl, 5 m M KCl, and is referred to as P. In addition to P, PCG 
contains,  5 m M CaCl 2 and 1 g/l  D -glucose  [42] . In addition to P, 
PACGM contains 3% human serum albumin, 1 m M CaCl 2 , 1 g/l 
 D -glucose, and 0.25 g/l MgCl 2  6H 2 O (pH 7.4). In addition to P, 
PGMD contains 0.25 g/l MgCl 2  6H 2 O, 10 mg/l DNase, and 1 g/l 
gelatin (pH 7.4). PBS contains 8 g/l NaCl, 1.15 g/l Na 2 HPO 4 , 200 
mg/l KCl, and 200 mg/l KH 2 PO 4 , pH 7.4.
 Purification of SV-IV 
 SV-IV was purified to homogeneity from the seminal vesicle 
secretion of adult rats (Fisher-Wistar strain) according to a previ-
ously published technique  [1] . The purity of the protein was eval-
uated by 15% PAGE under denaturing and nondenaturing condi-
tions, amino acid composition analysis, fingerprinting technique, 
and fast atom bombardment mass spectrometry  [15, 43] . Neither 
lipopolysaccharide nor TNF, as determined by specific biological 
assays  [44, 45] , was present in the SV-IV preparations. The con-
centration of purified SV-IV was measured by its molar extinc-
tion coefficient at 276 nm (4,100  M –1  cm –1 ), calculated on the ba-
sis of the tyrosine and phenylalanine residues present in the SV-
IV polypeptide chain  [11] .
 Mast Cell Culture 
 Human mast cell line (HMC-1) was donated by Dr. J.H. But-
terfield (Mayo Clinic, Rochester, Minn., USA); cells were main-
tained in a humidified incubator (37 ° C, 5% CO 2 ) in suspension 
culture at a concentration of 3–9  ! 10 5 cells/ml of Iscove’s Mod-
ified Dulbecco’s Medium supplemented with 10% FCS, 2 m M 
 L -glutamine, and 1.2 m M monothioglycerol  [46] .
 Cell Purification 
 Basophils 
 Basophils were purified from peripheral blood of healthy vol-
unteers, aged 20–39 years (33.6  8 4.9 years) and negative for HIV-
1 and HIV-2 antibodies. Buffy-coat cell packs were provided by 
the Immunohematology Service (University of Naples Federico 
II). Informed consent, according to the guidelines of the Univer-
sity of Naples Federico II institutional review board for the use of 
humans in research, was obtained. Cells were reconstituted in 
PBS containing 0.5 g/l human serum albumin and 3.42 g/l sodi-
um citrate and loaded onto a countercurrent elutriator (model 
J2–21; Beckman, Fullerton, Calif., USA). Several fractions were 
collected, and fractions containing basophils in large numbers 
( 1 20  ! 10 6 basophils) and of good purity ( 1 15%) were enriched 
by discontinuous Percoll gradients. Basophils were further puri-
fied to near homogeneity ( 1 98%) by removing B cells, monocytes, 
NK cells, dendritic cells, erythrocytes, platelets, neutrophils, eo-
sinophils, and T cells using a cocktail of hapten-conjugated CD3, 
CD7, CD14, CD15, CD16, CD36, CD45RA, and anti-HLA-DR an-
tibodies and MACS MicroBeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) coupled to an anti-hapten monoclonal antibody. 
The magnetically labeled cells were depleted by retaining them on 
a MACS column in the magnetic field of the MidiMACS (Milte-
nyi Biotec). Yields ranged from 3 to 10  ! 10 6 basophils, with pu-
rity usually  1 98%, as assessed by basophil staining with Alcian 
blue and counting in a Spiers-Levy eosinophil counter  [35] .
 Human Lung Mast Cells  
 Lung tissue was obtained from patients undergoing thoracot-
omy and lung resection. Macroscopically normal parenchyma 
was dissected free from pleura, bronchi, and blood vessels and 
minced into a single-cell suspension as previously described  [42] . 
Yields with this technique ranged between 3  ! 10 6 and 18  ! 10 6 
mast cells, and purities were between 1 and 8%. Human lung mast 
cells (HLMCs) were purified first by countercurrent elutriation 
(J2/21; Beckman) and then by discontinuous Percoll density gra-
dient as previously reported  [42] . Mast cells were further purified 
to near homogeneity by positive selection using an anti-CD117 
monoclonal antibody conjugated to magnetic beads and retaining 
labeled cells on a selection column (MACS system; Miltenyi Bio-
tec). The final preparations contained  1 95% viable cells, as as-
sessed by the trypan blue exclusion method and a lactate dehydro-
genase (LDH) assay, with a mast cell purity higher than 98%.
 Chemotaxis Assay 
 Basophil and mast cell chemotaxis experiments were carried 
out using a modified Boyden chamber technique. Briefly, 25   l of 
either PACGM buffer or various concentrations of chemoattrac-
tants in the same buffer were added in triplicate into the lower 
compartment of a 48-well microchemotaxis chamber (Neuro-
probe, Cabin John, Md., USA). The lower compartments were 
covered with polycarbonate membranes of 5.0   m pore size (ba-
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sophils) or with a two-filter sandwich constituted by 5-  m (low-
er) and 8-  m pore size (upper) polycarbonate membranes (mast 
cells); Nucleopore, Pleasanton, Calif., USA)  [35] . Fifty microliters 
of cell suspension (5  ! 10 4 /well) resuspended in PACGM were 
added into the upper compartment. The chemotactic chamber 
was incubated for 1 h (basophils) or 3 h (mast cells) at 37 ° C in a 
humidified incubator with 5% CO 2 (automatic CO 2 incubator, 
model 160 IR, ICN/Flow Laboratories). At the end of basophil in-
cubation, the membranes were removed, washed with PBS on the 
upper side, fixed, and stained with May-Grünwald/Giemsa. 
When mast cells were used, the upper polycarbonate filter was 
discarded, while the lower nitrate cellulose filter was fixed in 
methanol, stained with Alcian blue, and then mounted on a mi-
croscope slide with Cytoseal (Stephen Scientific, Springfield,
N.J., USA). Basophil and mast cell chemotaxis was quantified mi-
croscopically by counting the number of cells attached to the sur-
face of the 5-  m filter. In each experiment, 10 fields/triplicate 
filter were measured at 40 ! magnification.
 Checkerboard analyses were performed to discriminate be-
tween chemotaxis and chemokinesis (spontaneous nondirected 
migration) of cells. In these experiments, cells were placed in the 
upper chemotactic chambers and various concentrations of che-
moattractants or buffer were added to the upper or lower wells or 
to both. Chemokinesis was determined in the absence of che-
moattractants or when the latter were added to both the lower or 
upper chambers. The cell migratory response to SV-IV to chemo-
tactic stimuli was largely due to chemotaxis and not to chemoki-
nesis. Indeed, a checkerboard analysis, in which chemoattrac-
tants above and below the filters varied resulted in significant 
migration only when there was a gradient of the factor below the 
filters.
 Histamine Release Evaluation 
 Basophils (6  ! 10 4 basophils/test tube) or mast cells (3  ! 10 4 
cells/test tube) were resuspended in PCG, and 0.1 ml of cell sus-
pension was placed in 12  ! 75-mm polyethylene test tubes 
(Sarstadt, Princeton, N.J., USA) and warmed to 37 ° C. One hun-
dred microliters of each prewarmed releasing stimulus was added 
and incubation was continued at 37 ° C for 45 min. PCG  [47] was 
used in these experiments. At the end of this step, the reaction was 
stopped by centrifugation (1,000  g , 22 ° C, 2 min), and the cell-free 
supernatants were stored at –20 ° C for subsequent evaluation of 
the histamine level with an automated fluorimetric technique 
 [47] . Total histamine content was assessed by lysing the cells with 
2% HClO 4 before centrifugation. To calculate histamine release 
as a percentage of total cellular histamine, the spontaneous re-
lease of histamine from basophils and HLMCs (2–14% of the total 
cellular histamine) was subtracted from both the numerator and 
the denominator  [47] . The percentage of histamine release was 
calculated according to the equation [(A–B)/(T–B)]  ! 100, where 
A is the sample, B is the spontaneous histamine release, and T is 
the total histamine content. All values are based on means of du-
plicate or triplicate determinations. Replicates differed in hista-
mine content by  ! 10%.
 Cytokine and Vascular Endothelial Growth Factor A mRNA 
Evaluation by Real-Time PCR 
 Total RNA from HMC-1 cells was extracted by using the SV 
96 total RNA isolation system (Promega, Milan, Italy) and treated 
with RNase-free DNase I. Five micrograms of RNA were ret-
rotranscribed as previously described  [48] . cDNA was titrated for 
GAPDH mRNA and the expression of TGF-  1 , IL-10, IL-13, TNF-
  and vascular endothelial growth factor A (VEGF-A) mRNA was 
evaluated by real-time RT-PCR. The latter was performed with 
the iCycler (Bio-Rad) by using the PE SYBR Green PCR kit (Ap-
plied Biosystems, Foster City, Calif., USA). Target-specific prim-
ers for GAPDH and analyzed cytokines suitable for real-time 
PCR were used ( table 1 ). After an initial denaturation step at 95  ° C 
for 10 min, amplification was performed with 40 cycles of dena-
turation (95 ° C) for 30 s, annealing (56.5 ° C) for 30 s, and elonga-
tion (72 ° C) for 30 s. PCR efficiency was evaluated by serial dilu-
tions of template cDNA, and the melting curve data were collect-
ed to verify PCR specificity. Each cDNA sample was analyzed in 
triplicate and the corresponding no-RT mRNA sample was in-
cluded as a negative control. The mRNA signal for the cytokines 
in each sample was normalized to GAPDH mRNA. The data were 
analyzed by the iCycler iQ software (Bio-Rad) and the mRNA 
changes in different conditions were expressed as the ratio versus 
GAPDH.
 TGF-  1 and VEGF-A Release Assessment 
 For the evaluation of TGF-  1 and VEGF-A release we incu-
bated HMC-1 (37 ° C for 16 h in Iscove’s Modified Dulbecco’s Me-
dium containing 5% FBS) and basophils (37 ° C for 4 h in RPMI 
containing 5% FBS) with SV-IV (1–30   M ). TGF-  1 and VEGF-A 
release in the supernatant was measured by ELISA (R&D Systems, 
Minneapolis, Minn., USA) in duplicate determinations and the 
results were normalized for the protein content of each well.
 Evaluation of CD203c on Fc  RI+ Cell Surface 
 Staining was performed at 4 ° C for 30 min with 10   l/200   l 
cell suspensions of the marker antibodies: anti-CD203c-PE and 
anti-IgE-FITC. The negative controls consisted of isotype-
matched, directly conjugated nonspecific antibodies. Cells were 
Genes Oligonucleotide sense (5′–3′) Oligonucleotide antisense (5′–3′)
VEGF-A GTGAATGCAGACCAAAGAAAG AAACCCTGAGGGAGGCTC
IL-10 CTGCCTAACATGCTTCGAGA TGAGGGTCTTCAGGTTCTCC
TGF-β AGCCTGAGGCCGACTACTAC GAGGTATCGCCAGGAATTGT
IL-13 CCTCAATCCTCTCCTGTTGG CCACCTCGATTTTGGTGTCT
TNF-α GACAAGCCTGTAGCCCATGT CTGAGTCGGTCACCCTTCTC
GAPDH GCCAAAGGGTCATCATCTC GTAGAGGCAGGGATGATGTTC
Table 1. Sequence of primers used in the 
real-time RT-PCR analysis
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washed and analyzed with a FACSCalibur cytofluorimeter using 
CellQuest software (BD Bioscience, San Ferdinando, Calif., USA). 
A total of 10 4 events for each sample were acquired in all cyto-
fluorimetric analyses.
 Lactate Dehydrogenase Assay  
 LDH release at the end of the incubations served as an index 
of cytotoxicity. It was measured in cell-free supernatants using a 
commercially available kit (Sigma-Aldrich)  [35] .
 Statistics 
 The results are expressed as means  8 SEM. Values from 
groups were compared using the paired Student’s t test. Differ-
ences were considered significant when p  ! 0.05.
 Results 
 SV-IV Treatment of Basophils Induces Histamine 
Release but Not Cell Migration 
 In a first group of experiments, we assessed the effect 
of increasing concentrations of SV-IV on histamine re-
lease from purified peripheral blood basophils ( 1 98% 
pure) obtained from normal human donors. Basophils 
were incubated for 30 min at 37 ° C in the presence of pro-
gressively increasing concentrations of SV-IV (1–30   M ). 
Following incubation, the cells were eliminated by cen-
trifugation and histamine released in supernatant was 
evaluated as indicated in Materials and Methods. In a se-
ries of 6 experiments, treatment with SV-IV induced a 
significant concentration-dependent release of histamine 
(3.2  8 0.8% at 1   M SV-IV; 43.7  8 4.6% at 30   M SV-IV) 
( fig. 1 a). 
 In other experiments, the effect of SV-IV on basophil 
chemotaxis was studied with a modified Boyden cham-
ber  [42] . The results from 5 experiments demonstrated 
that SV-IV (1–30   M ) was unable to promote basophil 
migration ( fig. 1 b), in line with the known ability of SV-
IV to inhibit chemotaxis in human leukocytes  [20] .
 The concentrations of SV-IV used did not induce 
spontaneous LDH release from basophils (data not 
shown).
 Characteristics (Time Course, Temperature and 
Extracellular-Ca 2+ Dependence) of SV-IV-Induced 
Histamine Release 
 We first compared the kinetics (1–45 min) of hista-
mine release induced by 30   M SV-IV and 0.6 n M anti-
IgE in basophils. The time course of histamine release 
induced by SV-IV was slow, reaching a maximum at 
about 45 min after stimulus addition. In contrast, anti-
IgE-induced histamine release was significantly faster, 
being complete after only 15 min ( fig. 2 a). The difference 
between SV-IV and anti-IgE histamine-releasing rates 
implies possible differences in the release mechanism 
elicited by the two different stimuli.
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 Fig. 1.  a Effect of increasing concentrations (1–30   M ) of SV-IV 
on histamine release from human basophils: cells were challenged 
(45 min at 37 ° C) with the indicated concentrations of SV-IV; his-
tamine release was calculated as percentage of total cellular his-
tamine; the spontaneous release of histamine from basophils (2–
14% of the total cellular histamine) was subtracted from each de-
termination.  b Effect of increasing concentrations (1–30   M ) of 
SV-IV on the chemotaxis of human basophils. Cells were allowed 
to migrate for 1 h toward the indicated concentrations of SV-IV 
at 37 ° C in a humidified incubator in the presence of 5% CO 2 . Val-
ues are the means  8 SEM of 6 experiments with different cell 
preparations. Further experimental details are indicated in Mate-
rials and Methods. 
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 The temperature dependence of histamine-releasing 
activity of SV-IV on basophils was studied by stimulating 
these cells at 37, 30, 22, and 4 ° C.  Figure 2 b shows that the 
SV-IV-induced response was abolished by lowering the in-
cubation temperature from 37 ° C to 22 ° C or 4 ° C, a de-
crease of about 30% having been observed at 30 ° C. Similar 
results were obtained in other 2 identical experiments.
 The effect of increasing concentrations of extracellu-
lar Ca 2+ (0–5.0 m M ) on histamine-releasing activity of 
basophils in the presence of 10   M SV-IV was also inves-
tigated. The Ca 2+ increase progressively enhanced the 
SV-IV-induced histamine release ( fig. 2 c). This finding 
indicates a physiological interaction between SV-IV and 
basophils. It is worth noting that all the experiments re-
ported in this study were conducted with physiologic 
concentrations of extracellular Ca 2+ (2 m M ).
 SV-IV Does Not Induce LTC 4 Release from Basophils 
 The immunologic activation of human basophils, in 
addition to the secretion of preformed histamine, leads to 
de novo synthesis and release of LTC 4 through the 5-
 lipoxygenase pathway. In a series of 4 experiments, we 
compared the effects of 1–30   M SV-IV and 0.18–6 n M 
anti-IgE on the release of LTC 4 from basophils. SV-IV did 
not induce the release of LTC 4 from basophils. In contrast, 
anti-IgE markedly stimulated the release of LTC 4 (data 
not shown). This finding suggests that SV-IV could act as 
an incomplete secretagogue being able to release only his-
tamine and not de-novo-synthesized mediators.
 Synergy between SV-IV and Anti-IgE on Histamine 
Release from Basophils 
 Anti-IgE, which induces histamine release by cross-
linking cell surface IgE, was tested for synergy with SV-
IV.  Figure 3 shows that SV-IV promoted anti-IgE-in-
duced histamine release from basophils. More in details, 
treatment (10 min at 37 ° C) of these cells with 1–30   M 
SV-IV resulted in marked enhancement of histamine re-
lease by using optimal concentrations of anti-IgE (0.6 n M ) 
( fig. 3 ). The SV-IV/anti-IgE synergy demonstrated by 
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 Fig. 2.  a Kinetics of histamine secretion from human basophils 
induced at 37 ° C by anti-IgE (0.6 nn) ( + ) and SV-IV (30   M ) ( I ): 
each point represents the mean of duplicate determinations from 
a typical experiment out of 3 performed with similar results.
 b Effect of increasing concentrations of SV-IV on histamine re-
lease from basophils incubated for 60 min at 37 ° C ( I ), 30° C ( + ), 
22 ° C ( y ), or 4 ° C ( d ): each point represents the mean of duplicate 
determinations from a typical experiment out of 3 performed 
with similar results.  c  Effect of various concentrations of extra-
cellular Ca 2+ on histamine release induced by SV-IV (10   M ) from 
human basophils incubated for 60 min at 37 ° C. 
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these data indicates a possible molecular cross-talk be-
tween the two histamine-releasing mechanisms. Further 
experiments are warranted to elucidate the SV-IV hista-
mine-releasing mechanism.
 SV-IV Alone or in Synergy with Anti-IgE Induces 
Histamine Release from HLMCs 
 The heterogeneity of human basophils and mast cells 
prompted us to verify whether SV-IV could also induce 
histamine release from primary mast cells, easily puri-
fied in a sample from human resected lungs. For hista-
mine release experiments, we used primary mast cells, a 
more physiological model than the human leukemic mast 
cell line HMC-1.
 Figure 4 a shows that a 1–30   M SV-IV induced a sig-
nificant dose-dependent release of histamine in these 
cells (2.5  8 0.6% at 1   M SV-IV; 32.7  8 3.4% at 30   M 
SV-IV).
 Furthermore, to investigate whether SV-IV was able to 
potentiate histamine release induced by anti-IgE in 
HLMCs, cells were first preincubated with 1–30   M SV-
IV and then stimulated with 6 n M anti-IgE. The data ob-
tained show that SV-IV was able to potentiate (synergistic 
effect) the release of histamine induced by anti-IgE in the 
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 Fig. 3. Effect of preincubation (10 min at 37 ° C) with increasing 
concentrations (1–30   M ) of SV-IV on histamine release from hu-
man basophils induced by anti-lgE (0.6 n M ). Each point repre-
sents the mean of duplicate determinations from a typical exper-
iment out of 5 performed with similar results. 
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 Fig. 4.  a Effect of increasing concentrations (1–30   M ) of SV-IV 
on histamine release from HLMC: cells were challenged (45 min 
at 37 ° C) with the indicated concentrations of SV-IV; histamine 
release was calculated as percentage of total cellular histamine; 
the spontaneous release of histamine from human mast cells (2–
14% of the total cellular histamine) was subtracted from each de-
termination.  b Effect of preincubation (10 min at 37 ° C) with in-
creasing concentrations (1–30   M ) of SV-IV on histamine release 
from HLMCs induced by anti-lgE (6 n M ): each point represents 
the mean of duplicate determinations from a typical experiment 
out of 5 performed with similar results. 
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target cells only at its highest concentrations ( fig. 4 b). The 
concentrations of SV-IV used did not induce spontaneous 
LDH release from HLMCs (data not shown). 
 Genistein Does Not Inhibit SV-IV-Induced Histamine 
Release 
 To assess whether SV-IV-induced histamine release 
from basophils was tyrosine kinase (TK)-dependent, we 
tested the effects of genistein, a TK inhibitor, on SV-IV-
induced degranulation.
 Figure 5 shows the results from 3 experiments in which 
basophils were preincubated (30 min at 37 ° C) with opti-
mal concentrations of genistein (30   M ) before challenge 
(45 min at 37 ° C) with SV-IV (10–30   M ) or anti-IgE (0.6 
n M ). In none of the experiments did genistein cause inhi-
bition of histamine release induced by SV-IV. In control 
experiments, genistein inhibited anti-IgE-induced hista-
mine release. Similar results were obtained with HLMCs 
(data not shown). 
 These results are in line with the hypothesis that SV-
IV activates Fc  RI+ cells independently from tyrosine ki-
nase activity.
 SV-IV Does Not Influence the Expression of Cytokine 
mRNA in HMC-1 Cells 
 To verify whether SV-IV regulates the synthesis of 
anti-inflammatory and immunosuppressive cytokines in 
HMC-1, the real-time PCR was used to evaluate the effect 
of 30   M SV-IV on IL-10 and TGF-  1 mRNA expression. 
SV-IV was unable to upregulate expression after 16 h in-
cubation, whereas the phorbol myristate acetate (PMA;
4 n M ) and the calcium ionophore A23187 (200 n M ), used 
in combination as positive control, induced marked ex-
pression of these cytokine mRNAs ( fig. 6 a).
 To examine whether SV-IV regulates the synthesis of 
some immunostimulatory and proinflammatory cyto-
kines in HMC-1 cells, the effect of 30   M SV-IV on IL-13 
and TNF-  mRNA expression was evaluated by real-time 
PCR. SV-IV was unable to upregulate the mRNA expres-
sion of these cytokines after 16 h of incubation. The posi-
tive control (PMA + A23187), in contrast, induced marked 
expression of the same cytokine mRNAs ( fig. 6 b).
 The concentrations of SV-IV used did not induce 
spontaneous LDH release from HMC-1 cells after 16 h 
treatment (data not shown).
 SV-IV Does Not Modify VEGF-A mRNA Expression 
in HMC-1 Cells 
 To determine whether SV-IV regulates the synthesis 
of proangiogenic mediators in HMC-1 cells, real-time 
PCR was used to assess the effect of 30   M SV-IV on 
VEGF-A mRNA expression. SV-IV did not modify 
VEGF-A mRNA expression after 16 and 24 h of incuba-
tion, whereas 4 n M PMA and 200 n M A23187, used in 
combination as positive control, induced a marked ex-
pression of this mRNA ( fig. 6 c).
 SV-IV Does Not Influence the TGF-  1 Release from 
HMC-1 Cells 
 The data above reported demonstrate that SV-IV did 
not induce TGF-  1 mRNA expression in HMC-1 cells. 
We also evaluated the effect of 1–30   M SV-IV on TGF-
  1 release from the same cells after 24-hour incubation. 
SV-IV was unable to induce TGF-  1 release from HMC-1 
cells, whereas PMA (4 n M ) and A23187 (200 n M ), used in 
combination as a positive control, induced strong upreg-
ulation of this cytokine release ( fig. 7 ).
 The concentrations of SV-IV used did not induce 
spontaneous LDH release from HMC-1 cells after 24-
hour treatment (data not shown).
 SV-IV Does Not Influence the VEGF-A Release from 
Basophils 
 We also evaluated the effect of 1–30   M SV-IV on 
VEGF-A release from human basophils after 4-hour in-
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 Fig. 5. Effect of genistein on SV-IV-induced histamine release 
from basophils. Results of 3 independent experiments in which 
basophils were preincubated (30 min at 37 ° C) with optimal con-
centrations of genistein (30   M ) before challenge (45 min at 37 ° C) 
with SV-IV (10–30   M ) or anti-IgE (0.6 n M ). In none of the ex-
periments did genistein cause inhibition of histamine release in-
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IgE-induced histamine release. Values are the means  8 SEM of 3 
experiments with different cell preparations.  * p  ! 0.05 versus un-
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cubation. SV-IV was unable to induce VEGF-A release 
from these cells whereas anti-IgE (0.6 n M ), used as a pos-
itive control, induced upregulation of this cytokine re-
lease ( fig. 8 ).
 No increment in spontaneous LDH release was shown 
by basophils after 4 h of incubation with SV-IV.
 SV-IV Does Not Upregulate CD203c, an in vitro 
Marker of Fc  RI+ Cell Activation 
 CD203c, a type II transmembrane protein, has been 
described to be selectively expressed on basophils, mast 
cells and their CD34+ progenitors. As CD203c is rapidly 
upregulated after allergen challenge in sensitized pa-
tients, it has been proposed as a new tool for allergy diag-
nosis  [49] . We tested the effects of SV-IV protein (1-hour 
treatment, 30   M ) on CD203c expression on human ba-
sophils. The results of three independent experiments 
show that no CD203c overexpression can be observed af-
ter SV-IV treatment of basophils ( fig. 9 ). Similar results 
were also found by assessing the expression of CD63  [50] 
in the same cell system (data not shown).
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 Discussion 
 We demonstrated that SV-IV promotes the release of 
significant levels of histamine (degranulation effect) from 
mast cells and basophils without inducing other respons-
es including eicosanoid generation, cytokine production 
and chemotaxis. This unusual response for a normal se-
cretagogue was in part expected and consistent with the 
known biochemical and biological activities of SV-IV on 
its target cells such as: (a) the block of arachidonate cas-
cade via PLA 2 inhibition  [19, 21] ; (b) the modulation of 
cytokine generation in a positive or negative manner  [13, 
22–24] ; (c) the inhibition of human leukocyte chemotax-
is  [20] .
 Considering (a) the multifunctionality of SV-IV, (b) its 
ability to interact with the plasma membranes of differ-
ent target cells (T, B, and NK cells, macrophages/mono-
cytes, cancer cells, Fc  RI+ cells, blastomers, spermato-
zoa, platelets) and (c) its intrinsically disordered struc-
ture, a protein like SV-IV needs a large plasticity to 
efficiently interact with the different targets  [10] . With 
Fc  RI+ cell plasma membranes, SV-IV attained a par-
ticular structure more appropriate to produce a degranu-
lation effect rather than de novo synthesis of mediators. 
It has been shown that when bound to the plasma mem-
brane of resting human monocytes and lymphocytes, SV-
IV stimulates these cells to release de-novo-synthesized 
proinflammatory cytokines  [13] . In contrast, the latter 
event does not occur when SV-IV is bound to the surface 
of Fc  RI+ cells. 
 The time course of histamine release induced by SV-
IV in basophils was significantly slower than that in-
duced by anti-IgE. This finding is not so unusual because 
such slow kinetics is also known to be induced in baso-
phils by other stimuli (e.g. C5a, TPA), thus suggesting 
mechanisms of action different from that induced by 
anti-IgE  [51, 52] . 
 The possibility that histamine release induced by SV-
IV could be related to a generic toxicity or a proapoptotic 
effect of SV-IV on its target cells is, however, ruled out by 
several published data showing that SV-IV is nontoxic 
and strongly antiapoptotic  [17, 28] . In addition, treatment 
of Fc  RI+ cells with 10–30   M SV-IV in short- and long-
time incubations does not produce any significant change 
in cell viability, as measured by the LDH assay. The find-
ing that SV-IV operates on human basophils by a noncy-
totoxic mechanism is also supported by the fact that its 
histamine-releasing activity is temperature dependent. 
Finally, the ability of SV-IV to allow survival of dividing 
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murine zygotes up to the blastocyst stage in a culture me-
dium nonpermissive for embryo development further 
supports these findings  [17] .
 Neither CD203c nor CD63 were upregulated by SV-IV 
treatment of human basophils. This finding suggests that 
SV-IV, like diclofenac and other NSAIDs, stimulates 
Fc  RI+ cell degranulation without IgE intervention, thus 
promoting a pseudoallergic reaction in which this pro-
tein does not act as an IgE-interacting allergen  [50] .
 Treatment of SV-IV-target cells with the fluorescein-
ated or iodinated protein demonstrated the binding of 
this protein to their surface  [11, 17, 20, 24] . Furthermore, 
the molecular signaling of the antiapoptotic mechanism 
of SV-IV has been related to the protein tyrosine phos-
phorylation cascade induced by a PTK activity triggered 
by SV-IV binding to its lymphocyte plasma membrane 
putative receptors  [17] . On the contrary, as far as hista-
mine release from Fc  RI+ cells is concerned, SV-IV does 
not seem to operate via TK signaling, as suggested by our 
genistein experiments. 
 At the present time, on the basis of our data, the pro-
tein SV-IV could be considered an incomplete secreta-
gogue able to trigger histamine release from Fc  RI+ cells 
without stimulating the production or the release of oth-
er mediators  [53, 54] .
 Much work is still needed, however, for a better defini-
tion of the mechanism of action of SV-IV-stimulated his-
tamine release from Fc  RI+ cells. A receptor-indepen-
dent but membrane-assisted process induced by cationic 
secretagogues and involving G proteins may deserve in-
vestigation in these cells.
 The presence of the immunosuppressive and anti-
apoptotic SV-IV in uterus at the implantation site  [28] 
could contribute to the definition of the immunotolerant 
characteristics of the site. However, evidence that SV-IV 
is present in this location is only circumstantial: (a) SV-
IV is present in rat ejaculated semen in free and sperm-
bound form; (b) an SV-IV immunorelated protein has 
been found in rat uterine lysates and in human seminal 
plasma  [1, 14–16, 55, 56] . In rats, this speculation is sup-
ported by experiments demonstrating that the immuno-
genicity of blastocyst blastomeres is suppressed (about 
80%) by SV-IV  [28] . These SV-IV-induced immunosup-
pressive findings are in line with: (a) the ability of SV-IV 
to activate mast cell and basophil degranulation with re-
lease of immunosuppressive and antiapoptotic hista-
mine [ 38 and our data reported in this article]; (b) the 
ability of SV-IV to protect mouse zygote growth up to the 
blastocyst stage  [17] ; (c) other data showing the critical 
role of oxidative stress in jeopardizing embryo survival 
during early development  [57] , and (d) the protective ef-
fect of SV-IV on some target cancer cells (Raji, K562, 
DAUDI) against NK cytotoxicity  [28] . In conclusion, 
when analyzed in the context of other biological features 
of SV-IV, these findings provide a better understanding 
of its immune regulatory functions and also raise the 
possibility of a contributory role (at least in rodents) in 
the multifactorial orchestration at the uterine implanta-
tion site of maternal immunotolerance and blastocyst 
survival. 
 Furthermore, other data demonstrate that human em-
bryos at the preimplantation stage synthesize and secrete 
a protein, named embryo-derived histamine-releasing 
factor (EHRF), capable of inducing the release of hista-
mine from basophils and preimplantation uterine-de-
rived mast cells  [39, 58–60] . On the basis of these findings 
and by considering the immunosuppressive activity of 
histamine, the authors proposed a novel implantation 
model. This model suggests that the local secretion of his-
tamine in vivo by uterine Fc  RI+ cells, alone or in coop-
eration with other factors and/or mechanisms, could play 
a crucial role in preventing maternal immunorejection of 
the embryo allograft at the implantation stage  [39, 58–
60] . The immunosuppressive features of SV-IV could sig-
nificantly contribute to this model.
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